Should acellular pertussis vaccine be introduced into Sweden?
Kaijser, B.
Lakartidningen 85(42): 3447
1988
ISSN/ISBN: 0023-7205 PMID: 3199968 Document Number: 320298
Document emailed within 1 workday
Related Documents
Shek, L.Pei.Chi.; Khor, E.Sek.Hoon.; Tan, G.Huat.; Low, K.Tzay.; Ong, D.; Roy, J.; Han, H.Htay.; Bock, H.Ludwig.; Lee, B.Wah. 2003: Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants Southeast Asian Journal of Tropical Medicine and Public Health 34(4): 863-868Rennels, M.B.; Reed, G.F.; Decker, M.D.; Edwards, K.M.; Pichichero, M.E.; Deloria, M.A.; Englund, J.A.; Anderson, E.L.; Steinhoff, M.C.; Deforest, A. 1995: Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines Pediatrics 96(3 Pt 2): 576-579
Schmitt-Grohé, S.; Stehr, K.; Cherry, J.D.; Heininger, U.; Uberall, M.A.; Laussucq, S.; Eckhardt, T. 1997: Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group Developments in Biological Standardization 89: 113-118
Isomura, S.; Suzuki, S.; Sato, Y. 1985: Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients Developments in Biological Standardization 61: 531-537
Edwards, K.M.; Lawrence, E.; Wright, P.F. 1986: Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components American Journal of Diseases of Children 140(9): 867-871
Chuprinina, R.P.; Alekseeva, I.A.; Ozeretskovskiĭ, N.A. 2006: Prophylaxis of pertussis: development and use of acellular pertussis vaccine Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 2006(1): 99-105
Lin, T.-Y.; Wang, Y.-H.; Chang, L.-Y.; Chiu, C.-H.; Huang, Y.-C.; Tang, H.; Bock, H.L. 2003: Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age Chang Gung Medical Journal 26(5): 315-322
1992: ACIP issues statement on acellular pertussis vaccine American Family Physician 46(1): 286 291
Deloria, M.A.; Blackwelder, W.C.; Decker, M.D.; Englund, J.A.; Steinhoff, M.C.; Pichichero, M.E.; Rennels, M.B.; Anderson, E.L.; Edwards, K.M. 1995: Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations Pediatrics 96(3 Pt 2): 592-594
Dias, W.O.; Horton, D.S.; Takahashi, C.M.; Raw, I. 1994: A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction Brazilian Journal of Medical and Biological Research 27(11): 2607-2611
Giammanco, G.; Pignato, S.; Taormina, S.; Genovese, M.; Maggio, M.; Giammanco, A.; Anfuso, S.; Pittalà, D.; Li Volti, S.; Soncini, R. 1997: Immunization efficacy and tolerance of a tetravalent vaccine against diphtheria, tetanus, pertussis (acellular) and hepatitis B Annali di Igiene: Medicina Preventiva e di Comunita 9(3): 209-213
Isomura, S. 1991: Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan Developments in Biological Standardization 73: 37-42
1997: From the Centers for Disease Control and Prevention. FDA approval of a second acellular pertussis vaccine for use among infants and young children JAMA 277(10): 783
Bose, A.; Dubey, A.P.; Gandhi, D.; Pandit, A.; Raghu, M.B.; Raghupathy, P.; Rao, M.I.S.; Verghese, V.P.; Datta, S.K.; Bock, H.L. 2007: Safety and reactogenicity of a low dose diphtheria tetanus acellular pertussis vaccine (Boostrix) in pre-school Indian children Indian Pediatrics 44(6): 421-424
Abarca, K.; Valdivieso, F.; Potin, M.; Ibáñez, I.; Vial, P. 2002: Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults Revista Medica de Chile 130(5): 502-510
Chan, S.H.; Tan, P.T.N.; Han, H.H.; Bock, H.L. 2006: Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults Singapore Medical Journal 47(4): 286-290
Miura, S. 1968: Effects of the combined administration of a triple vaccine of pertussis, diphtheria and tetanus and virus vaccine (live polio vaccine or inactivated measles vaccine) on immunity to pertussis, diphtheria and tetanus. 1. Results of the initial immunization Nihon Shonika Gakkai Zasshi. Acta Paediatrica Japonica 72(6): 767-781
Corbel, M. J. 1993: Developments in Biological Standardization, volume 73. Pertussis: Evaluation and Research on Acellular Pertussis Vaccines Journal of Medical Microbiology 38(2): 155-156
Blumberg, D.A.; Pineda, E.; Cherry, J.D.; Caruso, A.; Scott, J.V. 1992: The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent American Journal of Diseases of Children 146(10): 1148-1150
Tiru, M.; Askelöf, P.; Granström, M.; Hallander, H. 1997: Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studies Developments in Biological Standardization 89: 239-245